Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Trandolapril; Verapamil

Criteria

Inclusion Criteria:

• Stage 1 or 2 Hypertension

Exclusion Criteria:

• Uncontrolled diabetes

• Subject has a hypersensitivity to ACE inhibitor